{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:10:17Z","timestamp":1788372617343,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jval.2022.08.013","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T12:02:39Z","timestamp":1666008159000},"page":"370-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone"],"prefix":"10.1016","volume":"26","author":[{"given":"Benjamin N.","family":"Rome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Egilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj G.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2022.08.013_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/cpt.1983","article-title":"Market exclusivity length for drugs with new generic or biosimilar competition, 2012-2018","volume":"109","author":"Rome","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jval.2022.08.013_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1001\/jamainternmed.2020.3588","article-title":"Assessment of variation in state regulation of generic drug and interchangeable biologic substitutions","volume":"181","author":"Sacks","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.jval.2022.08.013_bib3","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jval.2020.12.020","article-title":"Factors associated with generic drug uptake in the United States, 2012 to 2017","volume":"24","author":"Rome","year":"2021","journal-title":"Value Health"},{"issue":"26","key":"10.1016\/j.jval.2022.08.013_bib4","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1056\/NEJMc1711899","article-title":"Prices of generic drugs associated with numbers of manufacturers","volume":"377","author":"Dave","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jval.2022.08.013_bib5","author":"Conrad"},{"issue":"16","key":"10.1016\/j.jval.2022.08.013_bib7","first-page":"1563","article-title":"Authorized generics and their evolving role in prescription drug pricing and access","volume":"321","author":"Dusetzina","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jval.2022.08.013_bib9","author":"FDB."},{"key":"10.1016\/j.jval.2022.08.013_bib12","author":"Chahal"},{"issue":"12","key":"10.1016\/j.jval.2022.08.013_bib18","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.jval.2018.04.1827","article-title":"A\u00a0method for approximating future entry of generic drugs","volume":"21","author":"Beall","year":"2018","journal-title":"Value Health"},{"issue":"11","key":"10.1016\/j.jval.2022.08.013_bib19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1001\/jamainternmed.2017.4650","article-title":"Strategies that delay market entry of generic drugs","volume":"177","author":"Vokinger","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.jval.2022.08.013_bib20","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/jamainternmed.2020.2771","article-title":"US spending associated with transition from daily to 3-times-weekly glatiramer acetate","volume":"180","author":"Rome","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.jval.2022.08.013_bib21","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1377\/hlthaff.26.3.790","article-title":"Authorized generic drugs, price competition, and consumers\u2019 welfare","volume":"26","author":"Berndt","year":"2007","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.jval.2022.08.013_bib23","author":"Meier"},{"issue":"2","key":"10.1016\/j.jval.2022.08.013_bib24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamainternmed.2019.5161","article-title":"Confidentiality orders and public interest in drug and medical device litigation","volume":"180","author":"Egilman","year":"2020","journal-title":"JAMA Intern Med"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522021817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522021817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:31:51Z","timestamp":1761096711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522021817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1098301522021817"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.08.013","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}